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Cellular metabolism inﬂuences life and death decisions. An emerging theme in cancer biology is that metabolic regulation is
intricately linked to cancer progression. In part, this is due to the fact that proliferation is tightly regulated by availability
of nutrients. Mitogenic signals promote nutrient uptake and synthesis of DNA, RNA, proteins and lipids. Therefore, it seems
straight-forward that oncogenes, that often promote proliferation, also promote metabolic changes. In this review we summarize
our current understanding of how ‘metabolic transformation’ is linked to oncogenic transformation, and why inhibition of
metabolism may prove a cancer0s ‘Achilles’ heel’. On one hand, mutation of metabolic enzymes and metabolic stress sensors
confers synthetic lethality with inhibitors of metabolism. On the other hand, hyperactivation of oncogenic pathways makes
tumors moresusceptibletometabolicinhibition.Conversely,anadequatenutrientsupply andactivemetabolism regulatesBcl-2
family proteins and inhibits susceptibility to apoptosis. Here, we provide an overview of the metabolic pathways that represent
anti-cancer targets and the cell death pathways engaged by metabolic inhibitors. Additionally, we will detail the similarities
between metabolism of cancer cells and metabolism of proliferating cells.
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Facts
  Cancer cells proliferate rapidly thanks to metabolic
changes.
  Nutrients, particularly glucose and glutamine, are used by
cancer cells to produce ATP but also metabolites for growth.
  Oncogenic pathways such as those promoted by Ras,
PI3K or myc promote glycolysis, while tumor suppressors
like p53 inhibit it.
  Oncogenic transformation promotes sensitivity to inhibition
of certain metabolic pathways (synthetic lethality).
Open Questions
  Is there a speciﬁc metabolic proﬁle of tumor cells, different
to that of non-transformed proliferating cells?
  Which enzymes and metabolic pathways are regulated by
speciﬁc oncogenes?
  Which nutrients and metabolites are essential for which
type of cancer?
  What is the inﬂuence of diet on cancer development and
treatment?
  Can we develop non-toxic inhibitors of metabolic pathways
with clinical efﬁcacy?
All cells in our bodies require oxygen and nutrients. Energy is
constantly needed to perform cellular functions, from muscle
contraction to neuronal communication. Nutrients, however,
are not only required to produce energy. Cells are constantly
recycling components such as proteins and membranes and
damagedorganelles,andtheyalsoremodeltheircomponents
to adapt to new situations, and in this process they may need
new building blocks. In the case of cells induced to proliferate,
nutrients are needed in abundance for rapid growth. Cancer
cells therefore require a plentiful supply of nutrients. It has
been known for almost a century that metabolism of cancer
cells is ‘special’ because these cells consume glucose avidly
but they only use a small portion for oxidative phospho-
rylation (respiration) even in the presence of sufﬁcient
oxygen.
1 Instead, cancer cells utilise glycolysis, which yields
less ATP and can occur in hypoxic tissues which cannot
obtain ATP through respiration. A number of theories have
been proposed to explain this phenomenon known as
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www.nature.com/cddis‘the Warburg effect’. Amongst them, adaptation to tumor
hypoxia and inability to respire due to mitochondrial mutations
could be responsible for the shift to a glycolytic phenotype.
However, work in recent years has revealed that the glycolytic
switch is promoted by oncogenes and inhibited by tumor
suppressors, indicating that it is intrinsically associated with
oncogenic transformation.
2,3 Indeed, metabolic reprogram-
mingisnotonlyassociatedwithoncogenicmutations,butalso
with proliferation of non-transformed tissues. The glycolytic
switch and other metabolic changes also occur in normal cells
induced to proliferate such as activated T lymphocytes. From
this, numerous questions arise: is there a general metabolic
proﬁleoftumorcellswhichisdifferentfrommetabolismofnon-
cancerous but proliferating tissues? Can we exploit the
metabolic particularities of cancer cells without affecting
normaltissues?We willdiscussthemetabolicreprogramming
linked to proliferation, how oncogenic transformation drives
this reprogramming, and some features of cancer metabolism
that can be targeted.
Cell Proliferation and Oncogenesis are Coupled to
Metabolic Reprogramming
Proliferating cells have an increased uptake of glucose
and glutamine. Glucose is frequently metabolized through
glycolysis. Pyruvate, its product, enters the Krebs cycle or is
excreted as lactate. This step, conversion of pyruvate to
lactate is required to regenerate NAD
þ for glycolysis, and is
linked to oncogenesis as we will discuss later (Figure 1).
Glucose, together with amino acids, is also used to produce
nucleic acids through the pentose phosphate pathway.
Glycolytic intermediates are utilized by growing cells to
produce fatty acids and non-essential amino acids. Increased
glycolysis and lipid biosynthesis are characteristics common
to all highly proliferative cells, including activated T-cells
during acute stimulation and cells exposed to growth
factors.
4,5 Indeed, like cancer cells, these cells need to
support high proliferation rates and thus require efﬁcient
biosynthesis of macromolecules. Consequently, signals
leading to increased proliferation must also drive the
necessary adaptation to the new metabolic needs.
Growth factors activate Ras to transduce proliferation
signals. Not surprisingly, this protein is very often mutated
leading to its hyperactivation in cancer. Ras mediates the
activation of several effector pathways like PI3K/Akt and
MAPK pathways.
6–8 The PI3K/Akt pathway, which is also
activated by growth factors, leads to increased glycolysis
throughseveral ways. Akt promotes the increased expression
andmembranelocalization oftheglucosetransporterGLUT1,
it stimulates phosphofructokinase activity and the association
of hexokinases 1 and 2 with the mitochondria.
9–12 Down-
stream of Akt, mammalian Target of Rapamycin kinase
(mTOR) stimulates numerous metabolic pathways.
13 PI3K/
Akt/mTOR and MAPK pathways are involved in lipid
biosynthesis (Figure 2), notably through the SREBP depen-
dent transcription of several key enzymes such as ACL (ATP
citrate lyase) and FAS (fatty acid synthase).
14,15
MYC is activated by growth factors and it regulates the
transcription of thousands of genes or microRNAs involved in
cellular proliferation. Myc overexpression has been described
Figure 1 Metabolism of proliferating cells. Proliferating cells require glucose
which is converted to pyruvate through glycolysis. Pyruvate is converted to acetyl-
CoAwhichenterstheKrebs(TCA)cycleintheformofcitrate.Alternatively,citrateis
exportedbacktothecytosoltobeusedforlipidsynthesis.Glucosecanbealsoused
as a source of carbon to produce ribose through the pentose phosphate pathway.
Ribose-5-phosphate is then used to make RNA and DNA. Moreover, glycolytic
intermediatessuchaspyruvateareusedtoproducenon-essentialaminoacidssuch
as alanine. Cells also require amino acids such as glutamine to make other amino
acids and proteins. ‘Waste’is secreted in the formof lactate(mostly from glycolysis)
and ammonia (from catabolism to amino acids)
Figure 2 Signaling pathways that regulate metabolism of proliferating and
cancer cells. Growth factors inﬂuence metabolism through Ras and PI3K. Both
PI3K/Akt and MAPK increase glycolysis. They also induce the upregulation of the
transcription factor SREBP which promotes lipogenesis. mTOR, downstream of
PI3K/Akt also plays a central role in the metabolic switch observed in highly
proliferating cells: it activates protein translation, glycolysis (through HIF-1
dependent and independent pathways) and lipogenesis through the transcription
factors SREBP and Myc. Myc is also the main oncogene implicated in glutamine
addiction of cancer cells, through the upregulation of glutamate synthesis. It also
contributes to the Warburg effect by increasing glycolysis and lactate production.
AMPK activation, which is often impaired in tumors, allows the cells to switch their
metabolism to catabolism when the nutrients are scarce. p53 regulates metabolism
at multiple steps, notably through the upregulation of glutamate synthesis and
inhibition of fatty acid synthesis and glycolysis
40,119
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Cell Death and Diseasein many types of cancer. Myc has been shown to regulate
glutamine uptake and utilization in several ways.
16 For
instance, through the repression of miR-23a and miR-23b,
which leads to the induction of their target enzyme mitochon-
drial glutaminase 1.
17 This enzyme initiates mitochondrial
catabolism of glutamine to enter the Krebs cycle. On the other
hand, Myc promotes aerobic glycolysis by enhancing the
expression of GLUT1 and also of lactate dehydrogenase A,
which converts pyruvate to lactate and thereby contributes to
the Warburg effect.
18 Very recently, using a very powerful
spectrometric imaging system, Hu et al observed metabolic
changes in a model of c-myc driven oncogenesis and they
established that those metabolic changes preceded tumor
formation and were modulated by inactivation of c-myc.
19
This work identiﬁed modiﬁcations of glycolysis and alanine
synthesis pathways in pre-tumor stages. Alanine is synthe-
sized from pyruvate, and it is not the only amino acid
synthesized from glucose; serine and glycine are also
synthesized from glycolytic intermediates (Figure 3). This
highlights the relevance of glucose metabolism not only as a
source of ATP but also as a source of biosynthetic precursors
for cancer cells.
Regulation of Glycolysis by PKM2
The high proliferating rate of cancer cells forces them to
produce more energy but also more macromolecules.
Pyruvate kinase (PK) seems to play a key role in this context.
It is the ﬁnal enzyme of the glycolytic pathway converting
phosphoenolpyruvate into pyruvate with the production of
ATP (Figure 3). There are 4 forms of PK (L, R, M1 and M2)
derived from 2 distinct genes. PKM1 and PKM2 originate from
the same gene submitted to alternative splicing. The
alternative splicing in favor of PKM2 was shown to be
mediatedbythreeheterogeneousnuclearribonucleoproteins,
hnRNP1, hnRNPA1 and hnRNPA2, under the regulation of
the oncogene c-myc.
20 PKs are among the most regulated
enzymes of the glycolytic pathway.
21 PKM2 is of particular
interestinthecontextofcancerasitisthepredominantformof
PK in those cells. Whereas PKM1 is constitutively active with
a rapid substrate turnover, PKM2 can switch from high to low-
activity states depending on the cellular needs. In this sense,
pro-mitogenic signals, such as binding with phosphotyrosine
or phosphorylation by FGFR1, have been suggested to
promote cell and tumor growth by decreasing PKM2
activity.
22–24 In a counter-intuitive manner, this isoform of
PK which promotes glycolysis and the Warburg effect is less
efﬁcient than PKM1. Low activity of PKM2 is useful for cancer
cells because it promotes the use of glycolytic intermediates
forbiosynthetic pathways. mTORupregulates PKM2, andthis
effect was described as mediated though Hypoxia-Inducible
Factor (HIF)-1a, a transcription factor that reprograms cancer
cell metabolism, as we will discuss later.
25 Conversely, PKM2
was showntopromote transcriptionalactivityofHIF-1through
direct binding.
26 Altogether, this suggests that the paradoxical
low pro-glycolytic activity of PKM2 could be compensated by
an increase in HIF-1 transcriptional activity, what would
promote glycolysis at several levels.
Recently, a very exciting report established another reason
why cancer cells would beneﬁt from the expression of a less
efﬁcient PK isoform.
27 As mentioned above, by expressing
PKM2, cancer cells will accumulate several intermediates,
including phosphoenolpyruvate (PEP), the substrate for
pyruvate kinase in cells (Figure 3). The authors showed that
a phosphate group from PEP was transferred to the glycolytic
protein phosphoglycerate mutase 1 (PGAM1) what would
therefore increase its mutase activity. This provided an
efﬁcient mean to produce pyruvate in a PK-independent
Figure 3 Glucose metabolism in cancer cells. Glycolysis is a series of metabolic
processes, driven by nine speciﬁc enzymes, by which one mole of glucose is
catabolized to two moles of pyruvate, two moles of NADH with a net gain of two ATP.
Asindicated,severalintermediatescanfuelthePentosePhosphatePathwayorleadto
amino acid production. Accumulation of those intermediates is favored by the rate-
limiting activity of PKM2. In cancer cells, pyruvate is further converted into lactate,
thereby generating NAD
þ from NADH. Pyruvate can be imported in the mitochondrial
matrix to feed the TCA cycle. This step is controlled by Pyruvate Dehydrogenase
Kinase (PDK) which can inactivate Pyruvate Dehydrogenase (PDH), therefore limiting
the pyruvate conversion into acetyl-CoA and the further feeding of the TCA cycle.
K Transporters: Glut: Glucose transporter; MCT: monocarboxylate transporter.
K Glycolytic intermediates: G6P: Glucose-6-phosphate, F6P: fructose-6-phosphate;
F1,6BP: fructose-1,6-bisphosphate; F2,6BP: fructose-2,6-bisphosphate; DHAP:
dihydroxyacetone phosphate; GA3P: Glyceraldehyde-3-phosphate; 1,3-BPG:
1,3-bisphosphoglycerate; 3-PGA: 3-phosphoglycerate; 2-PG: 2-phosphoglycerate;
PEP: phosphoenolpyruvate;
K Enzymes: HK: hexokinase; PGI: phosphoglucoisomerase; PFK: Phosphofructoki-
nase; TPI: triose phosphate isomerase; GAPDH: Glyceraldehyde 3-phosphate
dehydrogenase; PGK: phosphoglycerate kinase; PGAM: phosphoglycerate
mutase; ENO1: enolase 1; PK: pyruvate kinase; LDH: lactate dehydrogenase.
K Chemicalinhibitorsareindicatedinbold;2DG: 2-Deoxy-Glucose;LND:Lonidamine;
3BrPA: 3-Bromopyruvate, KA: Koningic Acid; TLN-232 is a synthetic cyclic
heptapeptide which targets PK; DCA: Dichloroacetate
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Cell Death and Diseasemanner. One probable main advantage for cancer cells to use
thisPK-independentpathwayisthefailuretogenerateATPby
PK, because ATP can itself inhibit upstreams steps in
glycolysis. Therefore, cancer cells, by using a less efﬁcient
PK isoform, will activate this alternative pathway allowing the
dissociation between ATP production and the anabolic
processes that are required for fast cancer cell division.
Hypoxia and Cancer Metabolism
Variation of oxygen content is frequently observed in normal
tissuesasintumors.However, intumors,thegradientismuch
steeperasO2concentrationscan droptonear zero in necrotic
core areas. One main mechanism allowing cells to adapt to
hypoxia is mediated through the stabilization of the transcrip-
tionfactor HIF-1. Within anygivencell type, HIF-1 controlsthe
expression of hundreds of genes including several glycolytic
enzymes, glucose transporters, Lactate dehydrogenase
A and others.
28,29 In conditions where HIF-1a is stabilized
(hypoxicconditionsbutalsofollowinginactivatingmutationsin
tumor suppressor proteins) the capacity of tumor cells to carry
out glycolysis is increased. In addition, HIF-1 will activate
Pyruvate Dehydrogenase Kinase 1 (PDK1), a negative
regulator of the mitochondrial pyruvate dehydrogenase
complex and thereby reduce the ﬂow of pyruvate used by
the TCA cycle (Figure 3). Recently, dichloroacetate (DCA), a
PDK inhibitor, was administrated to ﬁve patients suffering
from glioblastoma, a very aggressive primary brain tumor with
limited therapeutic options.
30 This study established that DCA
was tolerated and also indicated that it could improve the
therapeutic response of patients. However, it is important to
note that a couple of relatively old studies reported nerve
toxicityofthisdrugsuggestingthatitsusewillprobablyhaveto
be restricted to selected patients.
31,32
Promoting Chemical Synthetic Lethality by Modulating
Cancer Metabolism
As discussed earlier, cancer cells use the same pathways
than proliferating cells to reprogram their metabolism and
stimulate proliferation (for reviews about regulation of
metabolism by oncogenes see Caims et al.
33 and Kroemer
et al.
34). There is a chance that metabolic targeting will thus
pose the same problems than conventional chemotherapy,
that is, that normal proliferative tissues will be affected.
However, our hopes lie in two aspects of cancer biology: (1)
the nutrient poor, hypoxic metabolic milieu that cancer cells
live in may make them more susceptible to metabolic
targeting, and (2) hyperactivation or inactivation of pathways
suchasmTORandp53willmaketumorsparticularlysensitive
to these therapies. Synthetic lethality arises when simulta-
neous mutation of two genes is lethal, while mutation of each
one alone is not (Figure 4). Chemical synthetic lethality is
obtained when inhibition of a gene product is lethal to cells
which present other mutations. Metabolic inhibition has been
shown to be synthetically lethal to cancer cells because
hyperactivation or oncogenes tends to make them ‘addicted’
to glucose or glutamine, but also because energetic stress
engages a ‘metabolic checkpoint’ which cannot occur in
cancer cells with certain mutations such as deﬁciency in p53.
Metabolic Checkpoint: p53, mTOR, AMPK
The p53 protein is coded by the TP53 gene, which is the most
frequently mutated gene in human tumours and functions as
the ‘guardian of the genome’.
35 p53 acts as a tetrameric
transcription factor that induces hundreds of target genes
involved in regulation of apoptosis, cell cycle and DNA repair
among others.
36 Loss of p53 promotes glycolysis (Figure 2).
p53 inactivation can lead to the Warburg effect by several
means, including the transcriptional regulation of TIGAR
(TP53-induced glycolysis and apoptosis regulator, a fructo-
se-2,6-bisphosphatase)
37 or the synthesis of the protein
SCO2 which is required for the correct assembly of the
cytochrome c oxidase (COX) complex of the electron
transport chain.
38 In addition, p53, like myc, promotes
glutamine utilization (Figure 2) by upregulating glutaminase
2; this is thought to participate in antioxidant responses
mediated by p53, because glutamine is required for glu-
tathione synthesis.
39,40 On the other hand, p53 is activated
whencellsundergometabolicorhypoxicstress.
35,41Cellsthat
lack p53 -like many tumor cells- cannot undergo a metabolic
checkpoint when glucose is scarce and they die.
42 Another
protein that participates in this checkpoint upstream of p53 is
the ATP sensor AMPK (AMP-activated protein kinase). This
protein promotes cell survival in the face of metabolic stress
by promoting cell cycle arrest, by downregulating anabolic
pathways and by promoting catabolism. On the other hand,
the AMPK activator LKB1 is absent in many tumors, which
makes these cells more sensitive to nutrient deprivation
because they cannot react and adapt to metabolic stress.
43
AMPK also participates in inactivation of mTOR, which is a
master regulator of protein translation and proliferation. This
protein, and the mTORC1 complex in which it is activated,
sense the nutritional status of the cells. If nutrients are absent,
cells do not synthesize proteins and they stop growing. But
when mTOR is hyperactivated, such as in an oncogenic
context by mutation of the tumor suppressor TSC, cells
become susceptible to glucose deprivation. These cells keep
Figure 4 Metabolic synthetic lethality. Synthetic lethality in organisms occurs
when the simultaneous mutation of two genes is lethal, while mutation in each
individualgene is not. Mutationsin certain genes that occurfrequentlyin cancer (for
instance,p53)promotesensitivitytoinhibitionofspeciﬁcmetabolicpathways,which
can be exploited to selectively target tumors with those mutations
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Cell Death and Diseasetrying to use nutrients for anabolic pathways because they
cannot match nutrient supply and demand. This causes
mTOR-mediated energetic stress and cell death.
44 This
indicates that loss of TSC, like loss of p53, promotes synthetic
lethality with blockade of glycolysis.
We have discussed above examples of signaling pathways
that promote synthetic lethality with metabolic inhibitors. But
importantly, metabolic enzymes themselves have also been
found altered in cancer. Some examples are isocitrate
dehydrogenases and phosphoglycerate dehydrogenase,
which will be discussed later. Fumarate hydratase (FH), an
enzyme of the TCA cycle is mutated in some tumors. Its
absence has recently been found to promote susceptibility to
inhibition of haem oxygenation, providing another example of
synthetic lethality.
45
Lactate
Lactate synthesis pathways, or pH changes associated with
lactic acid production are also susceptible to be targeted to
promote synthetic lethality. As we have discussed, trans-
formed cells convert a good proportion of incoming glucose to
lactate instead of metabolizing it through oxidative phosphor-
ylation, therefore creating an acidic microenvironment. The
local modiﬁcation of the microenvironment is supposed to
bring several advantages to the tumors: favoring invasion
46
and suppressing anticancer immune effectors.
47 Indeed,
lactate was reported as able to suppress the proliferation,
cytokine production and the cytolytic activity of cytotoxic T
lymphocytes (CTLs). However, it should be investigated
more thoroughly whether lactate production under aerobic
conditions is truly a selective feature of cancer cells and not of
other highly proliferating tissues.
Isocitrate Dehydrogenases (IDH1/2) and Oncometabolite
Production
Mutations in isocitrate dehydrogenases (IDH1 and IDH2)
genes have been linked to tumorogenesis.
48,49 IDH1 and
IDH2 are homodimeric enzymes that act in the cytoplasm and
in mitochondria respectively, to control one of the irreversible
steps in the TCA cycle essential for cellular respiration. Those
enzymes will convert isocitrate into a-ketoglutarate (a-KG)
generating carbon dioxide, NADH and NADPH as side
products. Their roles in cell growth are not interchangeable.
However, once mutated (on Arg132 for IDH1 and Arg140 and
172 for IDH2) both enzymes will further metabolize a-KG
into 2-hydroxy-glutarate (2-HG), which is regarded as an
‘oncometabolite’. Interestingly, in glioma and Acute Myeloid
Leukemia (AML) patients with IDH1/2 mutations, this meta-
bolite was found increased by 100-fold, suggesting that it
could be used as a clinical biomarker.
50,51 The function of
2-HG remains poorly understood but it is fascinating to note
that almost every IDH1 and IDH2 mutations were associated
with speciﬁc methylation proﬁles suggesting epigenetic
control. This is most likely promoted by the fact that the
lower level of a-KG and the accumulation of the antagonist
(2-HG) will prevent the activity of histone demethylases
(enzymes involved in epigenetic control).
52 In addition,
as 2-HG is an analogue of a-KG it will inhibit TET2, an
enzyme catalyzing the conversion of methylcytosine (5mC)
to 5-hydroxymethylcytosine (hmC). The exact function of
hmC is still unknown but it may inﬂuence chromatin structure
and seems to ultimately lead to base-excision repair and
de novo production of un-methylated cytosine.
53 It was also
reported that overexpression of IDH1 Arg132 mutants results
in elevated HIF-1a levels through an increase in 2-HG
production.
54 However a recent study indicated that an
upregulation of HIF by 2HG is unlikely to be the major factor
in IDH mutation-associated oncogenesis.
55 Even though
IDH1 and IDH2 were not the ﬁrst metabolic enzymes to be
involved in oncogenesis, they were the ﬁrst to link metabolite
production to oncogenesis
56 with major implications in basic
cancer biology (adding those enzymes to the list of cancer
genes) as in clinical considerations (such as diagnosis).
Active Metabolism Inhibits Cell Death
Glycolytic metabolism promotes proliferation of cancer cells,
but it also protects them from cell death. An increased
glycolytic rate renders cancer cells more resistant to
apoptosis induced by growth factor withdrawal. For example,
it was shown in leukemic cells that overexpression of
hexokinase 1 and GLUT1 was sufﬁcient for Akt to protect
against IL-3 withdrawal.
11 Under normal glucose conditions,
IL-3 withdrawal targets the antiapoptotic protein Mcl-1 for
proteasome degradation leading to cell death.
57 However,
when glucose levels are high, Mcl-1 is more stable
58
(Figure 5). Furthermore, if glycolysis is inhibited, the AMPK/
mTOR axis inhibits translation of Mcl-1, making cells more
susceptible to death ligands.
59 Inhibition of translation of
Mcl-1 through inhibition of metabolism may also represent a
new strategy tosensitize cellsto BH3 mimetics (personal data
and Coloff et al.
60). These drugs are inhibitors of the anti-
apoptotic proteins Bcl-2 and Bcl-xL which are attracting
attention as novel cancer therapeutics.
61–63
Figure 5 Regulation of cell death by glucose metabolism. Nutrient availability
regulates cell death induced by death receptors and by stimuli that kill through
the mitochondrial pathway by regulating the antiapoptotic Bcl-2 family member
Mcl-1, pro-apoptotic BH3-only proteins (Puma, Bim, Noxa and Bad) and c-FLIP.
64
Glucose deprivation induces necrosis (not shown), caspase-8 mediated –but death
receptor independent- apoptosis
120 or mitochondrial apoptosis mediated by Noxa,
Puma, Bad or Bim
41
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Cell Death and DiseaseAn increased glycolytic metabolism also inhibits expression
or activity of several pro-apoptotic BH3-only proteins, which
mediate death induced by physiological agents and che-
motherapeutic drugs
64 (Figure 5). For instance, overexpres-
sion of GLUT1 was shown to inhibit p53 and Puma induction
upon growth factor withdrawal.
41 Moreover, hexokinase1/
GLUT1 overexpression inhibited sensitivity of cells to trans-
fection of DNA encoding for Bim.
58 Metabolic stress has
been shown to regulate BH3-only proteins. For instance, high
glucose levels promote CDK5-mediated phosphorylation
and inactivation of Noxa in leukemic cells.
65 Additionally,
under low glucose conditions, Bad is dephosphorylated and
it induces apoptosis.
66
Besides the mitochondrial apoptotic pathway, it was shown
in several cancer cell lines that glucose deprivation induced a
drop in cFLIP levels and sensitization to death receptors.
67
Moreover, it was shown that maintenance of ATP production
throughkeepingmitochondriaactive, oroverexpressionofthe
glycolytic enzyme GAPDH promotes survival of cancer cells
even when they have undergone mitochondrial permeabiliza-
tion during apoptosis.
68–70 Thus, cancer cells may beneﬁt
from keeping an active metabolism not only because it is
required by proliferation, but also because it helps to escape
cell death.
Killing Cancer Cells by Inhibiting Glucose
Metabolism
Mosttumorsarehighlydependentonglucose.Overtheyears,
chemists have developed inhibitors against almost every step
of glycolysis that are being extensively tested in vitro, in vivo
and in clinical trials (Figure 3).
71,72 Targeting glucose
metabolism with agents such as 2-deoxyglucose may be
toxic at doses required to achieve tumor regression, although
this may depend on the type of tumor examined. Besides a
possible use as monotherapy, inhibitors of glucose metabo-
lism can enhance the efﬁcacy of chemo- and radiotherapy
(for an extensive review on the subject see Mijiyad et al.
64).
Some of these drugs are inexpensive, and combinations with
chemotherapy may be worth exploring in the clinic.
As discussed above, once pyruvate is produced, it can be
transformed into lactate to regenerate NAD for glycolysis
(Figures 1 and 3) or enter the mitochondria and support
the Krebs cycle. Lactate production and extrusion as well as
pH regulating systems could potentially be targeted to kill
or slow down proliferation of cancer cells,
73 although this
could also be potentially toxic for muscle. An interesting
approach discussed earlier is to promote the use of pyruvate
in the Krebs cycle and thus reduce lactate production
(Figure 3).
Factors that promote resistance to glycolysis inhibitors
includeapoptoticproteins.Itisthusrelevanttounderstandthe
mechanism of cell death induced by these drugs. Glucose
deprivation induces apoptosis or necrosis depending on the
cell type, and it is not understood what accounts for
the difference in response (for a review see Caro-Maldonado
et al.
74). Moreover, the apoptotic mediators seem to be
different depending on the cell type. Additionally, the
machinery of cell death engaged by glucose deprivation or
by glucose analogs can be different in the same cells
(Ramirez-Peinado et al.
75 and our unpublished observations).
It would be relevant to understand if some speciﬁc proteins
mediate cell death of tumor but not non-transformed cells.
Targeting Amino Acid Metabolism
The capacity of cancer cell to use glucose in support of
bioenergetic and macromolecular synthesis is not the only
particularity of cancer cell metabolism. In fact in the mid-20th
century Eagle observed that many cancer cells lines cannot
survive in absence of exogenous glutamine, therefore
suggesting the ‘glutamine addiction’ of some cancer cells.
76
It seems that glutamine, even if considered as a non-essential
amino acid that can be synthesized from glucose, is the
nitrogen donor for several key metabolic enzymes and for the
de novo synthesis of both purines and pyrimidines and it
appearstoberequiredforanabolicgrowthofmammaliancells
notably through its ability to control the master regulator of
proteintranslation mTORC1.
77 Finally, glutamineisalso a key
mitochondrial substrate required for maintenance of TCA
cycle and mitochondrial membrane potential.
78 For all those
reasons, several approaches were launched to target
glutamine addiction of those cancer cells (reviewed in Wise
and Thompson
79). One of these approaches is the use of
L-asparaginase, an asparagine-depleting enzyme which has
shown promising results for the treatment of pediatric acute
lymphoblastic leukemia (ALL).
80 This enzyme also depletes
glutamine, what correlates with its anti-tumor activity better
than its ability to deplete asparagine. Unfortunately, in adults,
L-Asparaginase has shown signiﬁcant toxicity.
81
Recently, using in vivo negative-selection RNAi screens,
Possemato et al. established that another amino acid
biosynthesis pathway, the serine pathway, is essential to
most estrogen negative breast cancers subtypes.
82 In the
same line, Vander-Heiden and colleagues showed that
phosphoglycerate dehydrogenase (PHGDH) which is found
overexpressed in some tumors, can divert glucose-derived
carbon into serine and glycine metabolism and that this
change can be selected for during the development of human
cancer.
83 These studies suggest that targeting this pathway,
at least in breast cancers presenting a high expression of
phosphoglycerate dehydrogenase, could represent an inno-
vative treatment modality. The apoptotic pathways engaged
by amino acid shortage have not been thoroughly explored,
but some reports indicate that cell death occurs via
mitochondrial apoptosis, possibly mediated by the Noxa/
Mcl-1 axis.
84,85
Targeting Lipid Metabolism
One additional feature of cancer cells is an increased rate of
lipogenesis. The newly synthesized lipids will be used for the
synthesis of membranes, notably lipid raft and lipid-modiﬁed
signaling molecules.
86 Lipid metabolism is increasingly seen
as potential target for anti-tumor therapy. Recently, a study
compared non tumoral cells with their Src or hRAS trans-
formed counterparts in order to identify a cancer cell
signature. This signature shows several common genes with
metabolic disorders, inﬂammation and immune responses.
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SNAP23 and VAMP4, which are involved in lipid metabolism,
cholesterol biosynthesis, and atherosclerosis.
87 One mole-
cule that has been driving increased interest recently
is SREBP (Sterol Regulatory Element-Binding Protein). This
transcription factor, which is a direct target of PI3K/Akt and
MAPKpathways,regulateslipidsynthesisanduptakethrough
upregulation of key enzymes of lipogenesis.
14,15 A speciﬁc
inhibitor of SREBP maturation, Betulin, induces cytotoxicity
of cancer cells.
88
Several enzymes implicated in lipogenesis have been
studied as potential target in anti-neoplastic therapy, like fatty
acid synthase (FAS), acetyl-CoA carboxylase (ACC) or ATP
citrate lyase (ACL). Their down regulation by siRNA expres-
sion or chemical inhibition leads to reduced proliferation of
the tumors.
89 ACL is responsible for the synthesis of acetyl
coAfromcitrate,anditsinhibitionleadsbothtotheinhibitionof
cholesterol synthesis and the inhibition of fatty acid synthesis
upstream of FAS. It thus appears as a key enzyme to target.
Indeed, the use of its chemical inhibitor SB-204990 reduced
cell growth and proliferation.
90 Recently, carnitine palmitoyl-
transferase 1C was shown to also be upregulated in cancer
cells,leadingtoincreasedfattyacidoxidation,ATPproduction
and resistance to hypoxia and glucose deprivation.
91 Statins
are inhibitors of cholesterol synthesis but also of the
production of molecules such as isoprenoids. These are lipid
anchors for a range of signaling proteins such as the small
GTPases Ras and Rho. Statins are commonly used to treat
cardio-vascular diseases. Interestingly, epidemiologic studies
indicate that their use reduces the incidence of some cancers,
and moreover, they can improve efﬁcacy of chemother-
apy.
92,93 However, their efﬁciency in anti-cancer therapy
remains to be studied thoroughly.
Targeting Nucleotide Metabolism
A group of compounds classically named ‘antimetabolites’
have been used for decades to treat cancer. These
compounds inhibit RNA and DNA synthesis. The widely used
drug 5-ﬂuorouracil (5-FU) exerts its toxic effects, in part, by
getting misincorporated into RNA. Additionally, its product
5-ﬂuorodeoxiuridine impairs DNA synthesis by blocking
thymidylate synthase. This enzyme is responsible for the
synthesis of deoxythymidine-triphosphate (dTTP). Thymidy-
late synthase is also the indirect target of methotrexate and
other, newer, anti-folate drugs. By inhibiting the synthesis of
dTTP these drugs impair DNA synthesis and promote DNA
damage. Since this pathway is more active in proliferating
cells than in normal cells, antimetabolites/nucleotide synth-
esisinhibitorsareeffectiveagainsttumors.
94,95Unfortunately,
like other metabolic inhibitors and chemotherapeutic drugs
they are also quite effective in killing hematopoietic cells and
other rapidly dividing cells.
Inhibition of nucleic acid synthesis can also occur as a
consequence of targeting other metabolic pathways. Nucleo-
tides are made de novo from amino acids and sugars
(Figure 1). The pentose phosphate pathway is required for
synthesis of nucleic acids, which means that drugs targeting
glucose uptake would also have an effect on RNA and DNA
synthesis. Additionally, depletion of selective amino acids
such as glutamine would also impair nucleotide synthesis.
Diet and Cancer
Diet has often been linked to longevity: reducing the calorie
intake can inﬂuence aging. The mechanism is being actively
researched, and it is thought to involve the inhibition of mTOR
and the activation of sirtuins.
96,97 In addition, diet is thought to
be a major contributory factor in the development and progre-
ssion of cancer. Epidemiological studies have highlighted that
the population having low sugar, low fat culinary traditions
present lower incidence of cancer.
98 Furthermore, studies in
mice have showed that feeding the animal a low carbo-
hydrate, high protein diet, not only decreased cancer
development but also reduced tumor growth.
99 Links between
diabetes and cancer have also been established. For
instance, it has long been observed that diabetic patients
exposed to metformin, a drug that reduces insulin tolerance,
have a decreased risk of cancer incidence.
100,101 Moreover,
metformin and other anti-diabetic drugs have been shown to
inhibit transformation.
87 It remains to be determined whether
these drugs act indirectly by regulating hormones, through an
effect of glucose availability on cancer cells or by directly
promoting cell death; metformin, for instance, inhibits mTOR
and promotes apoptotic cell death of cancer cells.
102
High-fat diets have been associated with cancer, and in
particular, prostate cancer.
103 An interesting study on the
monoacylglycerol lipase (MAGL) showed that the expression
of this enzyme correlated with tumor aggressiveness and
invasive phenotype. MAGL was acting through the release of
free fatty acids, and its knock down led to reduced invasive-
ness and tumor growth. Interestingly, the exogenous addition
of saturated fatty acids restored the migration ability of cells in
which MAGL was inhibited.
104 Besides the effects of high fat,
high protein or diabetes, caloric restriction per se has been
known to reduce cancer incidence.
105 One possible explana-
tion is that caloric restriction acts by altering insulin and IGF-1
levels, which work as growth factors for tumors. In this sense,
a study on rodents demonstrated that these growth factors
mediate the anti-tumoral effect of dietary restriction, and that
constitutive activation of PI3K rendered the cancer cells
resistant to diet restriction. This is the opposite of what would
be expected taking into account that hyperactivation of PI3K
promotes glycolysis and sensitivity to its inhibition. Clearly
morestudies needtobedone inordertostudywhethercaloric
restriction or selective reduction of carbohydrates or fats is
more effective, and whether the effects are due to metabolic
changes or hormonal changes. Furthermore, most of the
studies have been performed on laboratory rodents and need
to be veriﬁed in humans. A combination of adapted diet
(realistically applicable to humans) and chemotherapy might
be an interesting approach to consider in the future.
64,106
Conclusions and Perspectives
The ﬁeld of cancer metabolism is progressing rapidly. Recent
discoveries are prompting for a revision of biochemistry
textbooks. In the XXI century the focus has moved from
‘biochemical networks’ to ‘protein networks’ to understand
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107 However, we are still
making relevant discoveries like the existence of an alter-
native glycolytic pathway.
27 Besides the advance in basic
knowledge,manyquestionsremainastowhethermetabolism
represents the new cancer’s Achilles0 heel. We need to
identify which speciﬁc oncogenic mutations confer sensi-
tivity to inhibition of speciﬁc pathways (synthetic lethal
interactions). This would allow stratiﬁcation of patients in
future clinical trials.
A myriad of metabolic enzymes and pathways are awaiting
to be explored as targets for cancer therapy. In this regard,
metabolism is probably the research area that would beneﬁt
the most from application of systems biology methodology to
identify the key pathways. Additionally, metabolic proﬁling of
samplesfrompatients(Box1)wouldofferrelevantinformation
that may be hindered in most studies by the nutrient enriched,
high oxygen conditions in which cell lines are cultured. The
role of autophagy in survival to metabolic targeting still
requires clariﬁcation. Autophagy is a cellular response to
starvation which is also engaged by cell damaging agents,
including chemotherapy.
108–110 Although autophagy is a
survival response to many stimuli, in some contexts it
promotes apoptotic or non-apoptotic cell death.
111,112
Contradictory results exist in the literature regarding
a protective or pro-death role of autophagy in response to
energeticstressorischemia(see forinstance Altmanetal.,
113
Koike et al.
114 and Russo et al.
115).
Other interesting concepts that deserve more attention are
the effects of metabolic changes on tumor stroma (and vice
versa) and the role of redox metabolism and reactive oxygen
species (ROS) in tumor progression. Production and removal
of ROS is intimately linked to respiration and glucose and
glutamine metabolism. ROS have a dual role in cancer, as
signaling molecules that promote proliferation or as mediators
of cell death induced by chemotherapy or ischemia.
116–118
It is thus possible that some of the effects of metabolic
reprogramming are due to regulation of ROS detoxiﬁcation or
synthesis. Lastly, we should keep in mind that cancer is not
one disease, but hundreds of diseases, and for instance,
metabolism of melanoma or liver tumor are as different as the
shape or function of the tissues they originate from. Because
of the intensive research effort in this new, yet very old,
exciting ﬁeld, major discoveries likely await in the near future.
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